228 related articles for article (PubMed ID: 26381028)
1. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.
Garrido MC; Gutierrez C; Riveiro-Falkenbach E; Ortiz P; Rodriguez-Peralto JL
Am J Dermatopathol; 2015 Oct; 37(10):795-8. PubMed ID: 26381028
[TBL] [Abstract][Full Text] [Related]
2. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.
Hui Ong EL; Sinha R; Jmor S; Fearfield L
Am J Dermatopathol; 2019 Mar; 41(3):214-217. PubMed ID: 30601209
[TBL] [Abstract][Full Text] [Related]
3. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
5. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
Jansen YJ; Janssens P; Hoorens A; Schreuer MS; Seremet T; Wilgenhof S; Neyns B
Melanoma Res; 2015 Dec; 25(6):550-4. PubMed ID: 26512791
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
[TBL] [Abstract][Full Text] [Related]
7. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma.
Ramani NS; Curry JL; Kapil J; Rapini RP; Tetzlaff MT; Prieto VG; Torres-Cabala CA
Am J Dermatopathol; 2015 Aug; 37(8):e96-9. PubMed ID: 25839886
[TBL] [Abstract][Full Text] [Related]
8. Dabrafenib-associated necrobiotic granulomatous reaction.
Carlos G; Anforth R; Chou S; Fernandez-Peñas P
Australas J Dermatol; 2014 Nov; 55(4):306-8. PubMed ID: 25399793
[No Abstract] [Full Text] [Related]
9. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
[TBL] [Abstract][Full Text] [Related]
10. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
11. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
14. Pustular psoriasis eruption with dabrafenib, a BRAF inhibitor.
Fawaz B; Dickson L; Menter A
J Dermatolog Treat; 2016 Oct; 27(5):418-21. PubMed ID: 27080364
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
16. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors.
Falchook GS; Rady P; Konopinski JC; Busaidy N; Hess K; Hymes S; Nguyen HP; Prieto VG; Bustinza-Linares E; Lin Q; Parkhurst KL; Hong DS; Sherman S; Tyring SK; Kurzrock R
Arch Dermatol Res; 2016 Jul; 308(5):357-65. PubMed ID: 27098388
[TBL] [Abstract][Full Text] [Related]
17. Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib.
Sawada H; Kanehisa F; Katoh N; Asai J
J Dermatol; 2020 Jan; 47(1):e7-e8. PubMed ID: 31587335
[No Abstract] [Full Text] [Related]
18. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
19. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Ascierto PA; Simeone E; Sileni VC; Del Vecchio M; Marchetti P; Cappellini GC; Ridolfi R; de Rosa F; Cognetti F; Ferraresi V; Testori A; Queirolo P; Bernengo MG; Guida M; Galli L; Mandalà M; Cimminiello C; Rinaldi G; Carnevale-Schianca F; Maio M
Cancer Invest; 2014 May; 32(4):144-9. PubMed ID: 24484235
[TBL] [Abstract][Full Text] [Related]
20. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
[No Abstract] [Full Text] [Related]
[Next] [New Search]
